Form 4: AVITA Medical CFO Buys Shares

AVITA Medical's CFO, David O'Toole, acquired 2,000 shares of common stock.

Summary

• David O'Toole, Chief Financial Officer of AVITA Medical, Inc., purchased 2,000 shares of common stock on May 19, 2026.
• The purchase was made at a price of $4.24 per share.
• Following this transaction, Mr. O'Toole beneficially owns 143,927 shares of common stock.
• This transaction was made pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a CFO's personal investment, but the transaction occurred under a pre-arranged trading plan.

Positives

• CFO's personal investment in the company's stock, indicating confidence in the company's future.
• The transaction was executed under a Rule 10b5-1(c) trading plan, suggesting a pre-determined and structured approach to stock transactions, which can be viewed positively by investors as it mitigates concerns about insider trading based on material non-public information.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The purchase under a Rule 10b5-1 plan suggests a pre-determined strategy for stock transactions.

Industry Context

StockSavvy.ai notes that insider stock purchases, especially by a CFO, can be a signal of management's confidence in the company's prospects. However, the context of a Rule 10b5-1 plan is crucial, as it indicates the purchase was planned in advance and not necessarily a reaction to recent events.

Stakeholder Impact

• Shareholders may view the CFO's purchase as a positive signal of confidence in the company's future performance.
• The use of a Rule 10b5-1 plan may provide reassurance to investors regarding the transparency and fairness of insider trading activities.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, insider trading, stock purchase, CFO, beneficial ownership, Rule 10b5-1